116 related articles for article (PubMed ID: 9635845)
1. Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up.
Mauri FA; Caffo O; Veronese S; Verderio P; Boracchi P; Bonzanini M; Rossi N; Perrone G; Dalla Palma P; Barbareschi M
Br J Cancer; 1998 May; 77(10):1661-8. PubMed ID: 9635845
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
[TBL] [Abstract][Full Text] [Related]
3. Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up.
Veronese S; Mauri FA; Caffo O; Scaioli M; Aldovini D; Perrone G; Galligioni E; Doglioni C; Dalla Palma P; Barbareschi M
Int J Cancer; 1998 Feb; 79(1):13-8. PubMed ID: 9495351
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of estrogen receptors in breast carcinomas using monoclonal antibodies that recognize different domains of the receptor molecule.
Santeusanio G; Mauriello A; Ventura L; Liberati F; Colantoni A; Lasorella R; Spagnoli LG
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):275-84. PubMed ID: 11127919
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
6. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials.
Alberts SR; Ingle JN; Roche PR; Cha SS; Wold LE; Farr GH; Krook JE; Wieand HS
Cancer; 1996 Aug; 78(4):764-72. PubMed ID: 8756370
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval - prognostic implications?
Grabau DA; Bendahl PO; Rydén L; Stål O; Fernö M;
Acta Oncol; 2013 Nov; 52(8):1657-66. PubMed ID: 23343224
[TBL] [Abstract][Full Text] [Related]
8. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
[TBL] [Abstract][Full Text] [Related]
11. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.
Caffo O; Doglioni C; Veronese S; Bonzanini M; Marchetti A; Buttitta F; Fina P; Leek R; Morelli L; Palma PD; Harris AL; Barbareschi M
Clin Cancer Res; 1996 Sep; 2(9):1591-9. PubMed ID: 9816338
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
Thike AA; Chng MJ; Fook-Chong S; Tan PH
Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
[TBL] [Abstract][Full Text] [Related]
14. Expression of cell adhesion molecules and prognosis in breast cancer.
Saadatmand S; de Kruijf EM; Sajet A; Dekker-Ensink NG; van Nes JG; Putter H; Smit VT; van de Velde CJ; Liefers GJ; Kuppen PJ
Br J Surg; 2013 Jan; 100(2):252-60. PubMed ID: 23175431
[TBL] [Abstract][Full Text] [Related]
15. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
Breast; 2014 Dec; 23(6):754-62. PubMed ID: 25176593
[TBL] [Abstract][Full Text] [Related]
16. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
18. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma.
Jorns JM; Thomas DG; Healy PN; Daignault S; Vickery TL; Snider JE; Mardis ER; Davies SR; Ellis MJ; Visscher DW
Arch Pathol Lab Med; 2014 Nov; 138(11):1507-13. PubMed ID: 25357113
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of known prognostic factors in female breast carcinoma including oestrogen receptor, progesterone receptor and Her-2/neu status--a study in a tertiary care centre.
Chakrabarti S; Karmakar R; Barui G; Maity PK; Bandyopadhyay A; Roy A
J Indian Med Assoc; 2012 Dec; 110(12):876-9. PubMed ID: 23936949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
